Natixis Advisors L.P. Sells 19,134 Shares of Chemed Co. (NYSE:CHE)

Natixis Advisors L.P. lowered its stake in Chemed Co. (NYSE:CHE - Free Report) by 24.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,006 shares of the company's stock after selling 19,134 shares during the period. Natixis Advisors L.P. owned approximately 0.39% of Chemed worth $33,917,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CHE. Wealth Alliance raised its position in shares of Chemed by 3.0% during the 4th quarter. Wealth Alliance now owns 578 shares of the company's stock worth $338,000 after purchasing an additional 17 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of Chemed by 0.5% in the third quarter. Fifth Third Bancorp now owns 3,914 shares of the company's stock valued at $2,034,000 after acquiring an additional 21 shares in the last quarter. Legacy Wealth Asset Management LLC boosted its stake in shares of Chemed by 0.9% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 2,275 shares of the company's stock valued at $1,330,000 after acquiring an additional 21 shares during the last quarter. Signaturefd LLC increased its position in Chemed by 5.8% during the 4th quarter. Signaturefd LLC now owns 385 shares of the company's stock worth $225,000 after purchasing an additional 21 shares in the last quarter. Finally, Kestra Advisory Services LLC raised its stake in Chemed by 3.8% in the 3rd quarter. Kestra Advisory Services LLC now owns 634 shares of the company's stock valued at $329,000 after purchasing an additional 23 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Up 0.4 %

Shares of NYSE:CHE traded up $2.00 during trading on Friday, reaching $561.65. The stock had a trading volume of 70,751 shares, compared to its average volume of 83,809. The business has a fifty day moving average price of $620.66 and a 200-day moving average price of $593.70. The stock has a market cap of $8.50 billion, a P/E ratio of 30.23, a PEG ratio of 2.29 and a beta of 0.46. Chemed Co. has a fifty-two week low of $492.84 and a fifty-two week high of $654.62.

Chemed (NYSE:CHE - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $4.68 EPS for the quarter, missing the consensus estimate of $5.09 by ($0.41). Chemed had a return on equity of 30.52% and a net margin of 12.36%. The company had revenue of $589.23 million for the quarter, compared to analyst estimates of $587.18 million. As a group, equities analysts forecast that Chemed Co. will post 21.72 EPS for the current year.

Chemed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Monday, February 26th were given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.28%. The ex-dividend date was Friday, February 23rd. Chemed's dividend payout ratio (DPR) is 8.61%.

Insider Buying and Selling

In related news, VP Brian C. Judkins sold 11,158 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the completion of the transaction, the vice president now owns 1,422 shares of the company's stock, valued at $917,190. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Chemed news, EVP Spencer S. Lee sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the completion of the sale, the executive vice president now directly owns 20,760 shares in the company, valued at $13,320,654. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Brian C. Judkins sold 11,158 shares of the business's stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the sale, the vice president now owns 1,422 shares of the company's stock, valued at $917,190. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,808 shares of company stock valued at $10,184,531. Insiders own 3.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CHE. Oppenheimer lifted their price target on shares of Chemed from $625.00 to $650.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. Royal Bank of Canada boosted their price objective on shares of Chemed from $604.00 to $712.00 and gave the company an "outperform" rating in a research report on Monday, March 4th. Finally, StockNews.com raised shares of Chemed from a "hold" rating to a "buy" rating in a research report on Saturday.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.